Lv5
1240 积分 2022-05-24 加入
Target identification and assessment in the era of AI
3天前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
9天前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
11天前
已完结
Immunometabolism in systemic lupus erythematosus
20天前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
20天前
已完结
Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
23天前
已完结
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
23天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
Fibrosis in IBD: from pathogenesis to therapeutic targets
1个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
皖公网安备34019202002308
